SCHEMBL3671139

SCHEMBL3671139

CCCCC(=O)N1CCN(c2ccc(C(=O)NCCCN(C)C)cn2)CC1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
FOLH1 Q04609 1/20 0.47
NAMPT P43490 4/20 0.46
EGLN1 Q9GZT9 3/20 0.46
ME2 P23368 1/20 0.46
ME1 P48163 1/20 0.46
ME3 Q16798 1/20 0.46
POLB P06746 1/20 0.46
ALOX15 P16050 1/20 0.46
THRA P10827 1/20 0.45
THRB P10828 1/20 0.45
ALDH1A1 P00352 2/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
TSHR P16473 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
SCD O00767 2/20 0.45
RET P07949 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3678750 0.92 FOLH1 (0.51) NPC1RAB9AFOLH1NAMPTME2
SCHEMBL3676977 0.91 FOLH1 (0.52) NPC1RAB9AFOLH1ME2ME1
SCHEMBL3670671 0.90 FOLH1 (0.51) NPC1RAB9AFOLH1ME2ME1
SCHEMBL3673956 0.87 ME2 (0.51) NPC1RAB9AFOLH1EGLN1ME2
SCHEMBL3677186 0.86 ME2 (0.52) NPC1RAB9AFOLH1NAMPTME2
SCHEMBL3676988 0.86 SCD (0.47) NPC1RAB9AFOLH1NAMPTEGLN1
SCHEMBL3676844 0.85 ME2 (0.49) NPC1RAB9AFOLH1NAMPTEGLN1
SCHEMBL3673075 0.85 ENPP2 (0.46) NPC1RAB9AFOLH1EGLN1POLB
SCHEMBL3675138 0.85 SCD (0.61) NPC1RAB9AFOLH1NAMPTME2
SCHEMBL3671043 0.85 ALDH1A1 (0.60) NPC1RAB9AFOLH1NAMPTME2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1763350-B1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2011-12-21 EP claimed
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2009-08-06 US claimed
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2005-06-02 US claimed
EP-1763350-B1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2011-12-21 EP disclosed
EP-2266566-A2 Nicotinamide derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. (CA) 2010-12-29 EP disclosed
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2009-08-06 US disclosed
US-20070087363-A1 Therapeutic methods, compounds and compositions MYRIAD GENETICS, INCORPORATED (US) 2007-04-19 US disclosed
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents NAMPT, NNT, NNMT NPC1 94/4885RAB9A 1717/4885FOLH1 2800/4885
US-20070087363-A1 Therapeutic methods, compounds and compositions APP, BACE1, PSEN1 NPC1 31/4885RAB9A 1976/4885FOLH1 3029/4885
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS NAMPT, NNT, NNMT NPC1 94/4885RAB9A 1717/4885FOLH1 2800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.